|
Quotes & Info
|
| ARRY > SEC Filings for ARRY > Form 8-K on 4-Sep-2009 | All Recent SEC Filings |
4-Sep-2009
Other Events, Financial Statements and Exhibits
On September 3, 2009, Array BioPharma Inc. issued a press release announcing top-line results from rheumatoid arthritis phase 2 trial. The full text of this press release is attached hereto as Exhibit 99.1.
(d) Exhibits.
99.1 Press release dated September 3, 2009 entitled "Array BioPharma
Announces Top-Line Results From Rheumatoid Arthritis Phase 2 Trial."
99.2 Website slides dated September 3, 2009 entitled "ARRY-162-201: A
12-week, Phase 2, Randomized, Double-blind, Multicenter, Placebo
Controlled Study to Investigate the Safety, Pharmacokinetics and
Efficacy of ARRY-162, Administered Orally Daily in Patients with Active
Rheumatoid Arthritis Incompletely Responsive to Methotrexate-Top-Line
Results"
|
|
|